Catalyst
Slingshot members are tracking this event:
GSK plans to file its NDA seeking approval of its triple combination therapy for the treatment of chronic obstructive pulmonary disease (COPD) by the end of 2016
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| GSK | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 21, 2016
Occurred Source:
http://www.gsk.com/en-gb/media/press-releases/2016/gsk-files-regulatory-submission-in-us-for-once-daily-closed-triple-combination-therapy-ffumecvi-for-patients-with-copd/
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Chronic Obstructive Pulmonary Disease, Copd, Nda, Vilanterol, Umeclidinium, Fluticasone Furoate
